Slowing the progression of ankylosing spondylitis during long-term therapy with netakimab: results of the international multicenter randomized double-blind phase III clinical trial BCD-085-5/ASTERA

Objective. To evaluate the effect of long-term therapy with netakimab (NTK) on radiographic progression and reduction of inflammatory changes assessed by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS), and to identify factors influencing treatment response.
Material and methods. A post hoc analysis was performed on 228 patients with active AS who received NTK for 156 weeks in the randomized clinical trial BCD-085-5/ASTERA. The proportion of patients without radiographic progression was determined, defined as an increase in the mSASSS (modified Stoke Ankylosing Spondylitis Spinal Score) of <2 points from baseline to week 156. Additionally, the proportion of patients without any increase in mSASSS by week 156 was calculated. The proportions of patients without increases in the ASspi-MRI-a (Ankylosing Spondylitis spine MRI activity index) and SPARCC (Spondyloarthritis Research Consortium of Canada index), as well as with positive dynamics of these indices (reaching 0 or a ≥50% reduction from baseline at weeks 52, 104 and 156), were also assessed. The influence of baseline clinical and demographic factors on achieving a response by mSASSS, ASspi-MRI-a, and SPARCC was analyzed using univariate and multivariate logistic regression models.
Results and discussion. Among 228 patients, 66% showed no radiographic progression and 63% had no increase in mSASSS at week 156 compared with baseline. Positive dynamics in ASspi-MRI-a and SPARCC indices were demonstrated during two years of NTK therapy, with sustained effect through week 156. In univariate logistic regression, younger age (p=0.013) and absence of syndesmophytes or spinal ankylosis at baseline (p<0.01) were associated with lower rates of radiographic progression by mSASSS. Multivariate analysis did not reveal significant influence of baseline clinical-demographic or disease-history factors on NTK treatment response.
Conclusion. Long-term therapy with NTK prevents radiographic progression and reduces active inflammatory changes by MRI in the majority of AS patients, regardless of baseline clinical and demographic characteristics or prior tumor necrosis factor α inhibitor therapy.

1. Navarro-Compan V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021 Dec;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035.

2. Poddubnyy D, Sieper J. Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep. 2017 Sep;19(9):55. doi: 10.1007/s11926-017-0681-5.

3. Sepriano A, Ramiro S, Landewe R, et al. Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? real-life data from the ASAS and DESIR cohorts. Rheumatology (Oxford). 2019 May 1;58(5):798-802. doi: 10.1093/rheumatology/key387.

4. Erdes ShF, Korotaeva TV. Progression of axial spondyloarthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021; 15(3):7-14. (In Russ.). doi: 10.14412/1996-7012-2021-3-7-14

5. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014 Aug;73(8):1455-61. doi: 10.1136/annrheumdis-2014-205178.

6. Dinneen B, O'Shea F, Gensler L. Structural disease modification in axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2023 Sep; 37(3):101898. doi: 10.1016/j.berh.2023.101898.

7. Kim HJ, Seo SJ, Kim JY, et al. IL-17 promotes osteoblast differentiation, bone regeneration, and remodeling in mice. Biochem Biophys Res Commun. 2020 Apr 16;524(4): 1044-50. doi: 10.1016/j.bbrc.2020.02.054.

8. Mazurov VI, Gaydukova IZ, Erdes Sh, et al. Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized doubleblind clinical trial BCD-085-5/ASTERA. Nauchno-prakticheskaya revmatologiya. 2020; 58(4):376-386. (In Russ.).

9. Mazurov VI, Erdes ShF, Gaydukova IZ, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085- 5/ASTERA. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2020;14(4): 39-49. (In Russ.). doi: 10.14412/1996-7012-2020-4-39-49

10. Mazurov VI, Erdes ShF, Gaydukova IZ, at al. Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(1):35-46. (In Russ.). doi: 10.14412/1996-7012-2024-1-35-46

11. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296.

12. Van der Heijde D, Braun J, Deodhar A, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2019 Mar 1;58(3):388-400. doi: 10.1093/rheumatology/key128

13. Baraliakos X, Gensler LS, D'Angelo S, et al. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. Ther Adv Musculoskelet Dis. 2020 Mar 4;12: 1759720X20906040. doi: 10.1177/1759720X20906040.

14. Lee TH, Koo BS, Nam B, et al. Age-stratified trends in the progression of spinal radiographic damage in patients with ankylosing spondylitis: a longitudinal study. Ther Adv Musculoskelet Dis. 2022 May 23;14:175972 0X221100301. doi: 10.1177/1759720X221100301

15. Ramiro S, Stolwijk C, van Tubergen A, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015 Jan;74(1):52-9. doi: 10.1136/annrheumdis-2013-204055.

16. Baraliakos X , Gensler LS, D’Angelo S, et al. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. Ther Adv Musculoskelet Dis. 2020 Mar 4:12: 1759720X20906040. doi: 10.1177/1759720X20906040.

17. Baraliakos X, Braun J. Imaging Scoring Methods in Axial Spondyloarthritis. Rheum Dis Clin North Am. 2016 Nov;42(4):663-678. doi: 10.1016/j.rdc.2016.07.006.

18. Poddubnyy D, Sieper J. Mechanism of New Bone Formation in Axial Spondyloarthritis. Curr Rheumatol Rep. 2017 Sep; 19(9):55. doi: 10.1007/s11926-017-0681-5.

19. Ashany D, Stein E, Goto R, Goodman S. The effect of TNF inhibition on bone density and fracture risk and of IL17 inhibition on radiographic progression and bone density in patients with axial spondyloarthritis: a systematic literature review. Curr Rheumatol Rep. 2019 Mar 12;21(5):20. doi: 10.1007/s11926-019-0818-9.